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Abstract
Alzheimer’s disease is a progressive form of dementia that results in problems with
memory, thinking and behavior. It often starts with abnormal aggregation and de-
position of β amyloid and tau, followed by neuronal damage such as atrophy of the
hippocampi, and finally leads to behavioral deficits. Despite significant progress in
finding biomarkers associated with behavioral deficits, the underlying causal mech-
anism remains largely unknown. Here we investigate whether and how hippocam-
pal atrophy contributes to behavioral deficits based on a large-scale observational
study conducted by the Alzheimers Disease Neuroimaging Initiative (ADNI). As a
key novelty, we use 2D representations of the hippocampi, which allows us to bet-
ter understand atrophy associated with different subregions. It, however, introduces
methodological challenges as existing causal inference methods are not well suited
for exploiting structural information embedded in the 2D exposures. Moreover, our
data contain more than 6 million clinical and genetic covariates, necessitating ap-
propriate confounder selection methods. We hence develop a novel two-step causal
inference approach tailored for our ADNI data application. Analysis results suggest
that atrophy of CA1 and subiculum subregions may cause more severe behavioral
deficits compared to CA2 and CA3 subregions. We further evaluate our method
using simulations and provide theoretical guarantees.
Keywords: 2D treatment, confounders, hippocampus, genetics, imaging.
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1 Introduction
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly destroys
memory and thinking skills. According to World Alzheimer Reports (Gaugler et al., 2019), there
are around 55 million people worldwide living with Alzheimer’s disease and related dementia.
The total global cost of Alzheimer’s disease and related dementia was estimated to be a trillion
US dollars, equivalent to 1.1% of global gross domestic product. Alzheimer’s patients often
suffer from behavioral deficits including memory loss and difficulty of thinking, reasoning and
decision making.
In the current model of AD pathogenesis, it is well established that deposition of amyloid
plaques is an early event that, in conjunction with tau pathology, causes neuronal damage. Sci-
entists have identified risk genes (Morishima-Kawashima and Ihara, 2002) that may cause the
abnormal aggregation and deposition of the amyloid plaques. The neuronal damage typically
starts from the hippocampus and results in the first clinical manifestations of the disease in
the form of episodic memory deficits (Weiner et al., 2013). Specifically, Jack Jr et al. (2010)
presented a hypothetical model for biomarker dynamics in AD pathogenesis, which has been
empirically and collectively supported by many works in the literature. The model begins with
the abnormal deposition of β amyloid (Aβ) fibrils, as evidenced by a corresponding drop in
the levels of soluble Aβ-42 in cerebrospinal fluid (CSF) (Shaw et al., 2009; Aizenstein et al.,
2008). After that, neuronal damage begins to occur, as evidenced by increased levels of CSF
tau protein (Hesse et al., 2001). Numerous studies have investigated how Aβ and tau impact the
hippocampus (Ferreira and Klein, 2011), known to be fundamentally involved in acquisition,
consolidation, and recollection of new episodic memories (Frozza et al., 2018). In particular, as
neuronal degeneration progresses, brain atrophy, which starts with hippocampal atrophy (Braak
et al., 1993; Fox et al., 1996), becomes detectable by magnetic resonance imaging (MRI). As
sufficient brain atrophy accumulates, it results in cognitive symptoms and impairment. This
process of AD pathogenesis is summarized by the flow chart in Figure 1.
Figure 1: A hypothetical model of AD pathogenesis by Jack Jr et al. (2010). The red arrow
denotes the causal effect we are interested in estimating.
The aim of the paper is to answer whether (and how) brain changes, more specifically
hippocampal changes, affect the behavioral deficits in Alzheimer’s studies. Histological studies
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have shown that the hippocampus is particularly vulnerable to Alzheimer’s disease pathology
and has already been considerably damaged at the first occurrence of clinical symptoms (Braak
and Braak, 1998). Therefore, the hippocampus has become a major focus in Alzheimer’s studies
(De Leon et al., 1989). Specifically, pathological and MRI studies show that hippocampal
formation is severely atrophied in established Alzheimer’s disease (Fox et al., 1996). Previous
studies have found strong associations between hippocampal atrophy and behavioral deficits
(Whitwell et al., 2007). Recently, there has been a growing interest in going beyond association
and assessing causation to better understand the causes of the behavioral deficits. One particular
question of interest is whether hippocampal atrophy is a cause of behavioral deficits. Some
neuroscientists conjecture that the association between hippocampal atrophy and behavioral
deficits is causal, because the former destroys the connections that help the neuron communicate
and results in a loss of function (www.healthline.com/health/brain-atrophy).
In this article, we will develop new statistical tools to assess the causal relationship be-
tween hippocampal atrophy and behavioral deficits in an Alzheimer’s study. A randomized trial
to alter the brain size is clearly unethical. Instead, we based our analysis on a large-scale obser-
vational study by the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The ADNI study is
a world-wide research project aiming to improve the prevention and treatment of Alzheimer’s
disease. We use the Alzheimer’s Disease Assessment Scale cognitive score to quantify behav-
ioral deficits, where higher score indicates more severe behavioral deficits. Our exposure of
interest is hippocampal morphometry surface measure, summarized as two 100× 150 matrices
corresponding to the left/right hippocampus. Each element of the matrices is a continuous-
valued variable, representing the radial distance from the corresponding coordinate on the hipp-
pocampal surface to the medial core of the hippocampus. Compared with the conventional
scalar measure of hippocampus atrophy (Jack et al., 2003), recent studies show that the ad-
ditional information contained in the hippocampal morphometry surface measure is valuable
for Alzheimer’s diagnosis (Thompson et al., 2004; Zhang et al., 2016). For example, Li et al.
(2007) showed that the surface measures of the hippocampus can provide more subtle indexes
compared with the volume differences in discriminating between patients with Alzheimer’s and
healthy control subjects. In our case, with the 2D matrix radial distance measure, one may iden-
tify how local changes of hippocampal subfields affect the behavioral deficits. In addition, the
ADNI study measures ultra-high dimensional baseline covariates, including more than 6 million
genetic variants on several hundreds of subjects. The special structure of the ADNI data appli-
cation presents new challenges for statistical analysis. First, unlike conventional causal analysis
that deals with a scalar treatment, our exposure of interest is represented by high-dimensional
2D hippocampal imaging measures. Second, the dimension of baseline covariates, which are
also potential confounders, is much larger than the sample size.
Recently there have been many developments for confounder selection in the case of uni-
variate binary or continuous treatment. The conventional approach is to adjust for all baseline
covariates (Rubin, 2009). Recent studies, however, have shown that inclusion of the variables
only associated with the exposure but not the outcome (known as instrumental variables) may
result in loss of efficiency in the causal effect estimate (e.g. Schisterman et al., 2009), while
inclusion of variables only related to the outcome but not the exposure (known as precision
variables) may provide efficiency gains (e.g. Brookhart et al., 2006); see Richardson et al.
(2018) and references therein for an overview. Therefore, when a large number of covariates
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are available, our goal is to include all confounders and precision variables, while excluding
all instrumental variables and irrelevant variables (not related to both outcome and exposure).
To accomplish this goal, Shortreed and Ertefaie (2017) proposed an outcome-adaptive lasso ap-
proach that selects appropriate covariates for inclusion in propensity score models to account for
confounding bias and maintain statistical efficiency. Ertefaie et al. (2018) proposed a variable
selection method using a penalized objective function that is based on both the outcome and
treatment assignment models, facilitating confounder selection in high-dimensional settings.
The confounder selection problem was also investigated in VanderWeele and Shpitser (2011);
Wang et al. (2012); Vansteelandt et al. (2012); Wilson and Reich (2014); Schnitzer et al. (2016);
Antonelli et al. (2019), among others. However, these methods are not directly applicable to
our ADNI data for two reasons. First, all the methods are developed for univariate binary or
continuous treatment, and thus they are not directly applicable to our 2D high-dimensional con-
tinuous imaging treatment. Second, we have ultra-high dimensional baseline covariates (more
than 6 million covariates), which makes the current penalization or Bayesian based confounder
selection procedures computationally infeasible.
To address these challenges, we develop a novel two-step approach to estimate the causal ef-
fect of high-dimensional 2D hippocampal surface exposure on the Alzheimer’s behavior score,
while taking into account the ultra-high dimensional baseline covariates. The first step is a fast
screening procedure based on both outcome and treatment generating models to rule out most
of the irrelevant variables. The use of both models in screening is crucial for both computational
efficiency and selection accuracy, as we will show in detail in Section 3.3. The second step is a
penalized regression procedure for the outcome generating model to further exclude instrumen-
tal and irrelevant variables, and simultaneously estimate the treatment effect. Our simulations
and ADNI data application demonstrate the effectiveness of the proposed procedure.
Our analysis represents a novel inferential target compared to recent developments in imag-
ing genetics mediation analysis (Bi et al., 2017; Khadka et al., 2016). Although we consider a
similar set of variables and causal structure among these variables as illustrated later in Figure
2, our goal is to estimate the causal effect of hippocampal atrophy on behavioral deficits. In
contrast, in mediation analysis (Figure 4), researchers are often interested in the causal effects
of genetic factors on behavioral deficits, and how those are mediated through hippocampal at-
rophy. Direct application of methods developed for imaging genetics mediation analysis to our
problem may select genetic factors that are a subset of confounders having effects on both hip-
pocampal atrophy and behavioral deficits. As discussed above, omitting the precision variables
may inflate the variance of our causal effect estimate, and hence these precision variables should
in fact be included in the adjustment set.
We summarize our main contributions as follows. Our work holds the potential to be the
very first study of its kind investigating the causal relationship between complex neuroimaging
data and human behavior using observational data. By developing a two-step causal inference
procedure for high dimensional confounder selection and 2D treatment effect estimation, we
are able to identify important biomarkers that need to be adjusted in making causal inference
and locate subregions of the hippocampus that affect the behavioral deficits. To the best of
our knowledge, this is the first time that 2D continuous treatment is studied in causal inference
literature. Our result promises to unravel the underlying causal mechanism of behavioral deficits
and help early Alzheimer’s disease diagnosis.
5
The rest of the article is organized as follows. Section 2 includes detailed data and prob-
lem description. We introduce our model and two-step causal inference approach in Section 3.
We analyze the ADNI data and estimate the causal effect of hippocampal atrophy on behav-
ioral deficits in Section 4. Simulations are conducted in Section 5 to evaluate the finite-sample
performance of the proposed method. Section 6 investigates the theoretical properties of our
procedure. We finish with a discussion in Section 7.
2 Data and problem description
Understanding how human brains work and how they connect to human behavior is a central
goal in medical studies. Traditionally, cognitive neuroscientists have been probing the rela-
tionship between brain atrophy and behavior using neuroimaging data collected by means of
Magnetic Resonance Imaging (MRI) and Functional Magnetic Resonance Imaging (fMRI). The
results usually reflect a correlation rather than a causal relation. Cognitive neuroscientists ha-
bitually deny that imaging data can provide causal information about the relationship between
brain and behavior. However, recent studies have found evidence for the causal relationship
between atrophy of certain brain regions and behavioral deficits (Godefroy et al., 1998; Rigoux
and Daunizeau, 2015; Weber and Thompson-Schill, 2010).
In this paper, we are interested in studying whether (and how) hippocampal atrophy af-
fects behavioral deficits in Alzheimer’s studies. We consider the clinical, genetic, imaging and
behavioral measures in the ADNI dataset. The outcome of interest is the Alzheimer’s Dis-
ease Assessment Scale cognitive score observed at 24 months after baseline measurements.
The Alzheimer’s Disease Assessment Scale cognitive score, often referred to as the ADAS-11
(Rosen et al., 1984), consists of 11 items: word recall task, naming objects and fingers, fol-
lowing commands, constructional praxis, ideational praxis, orientation, word recognition task,
remembering test directions, spoken language, comprehension, and word-finding difficulty. A
higher ADAS-11 score indicates more severe behavioral deficits. The ADAS-11 score is a
widely used measure of cognitive behavior for Alzheimer’s disease, and has been shown to
have high test-retest reliability (Rosen et al., 1984) and moderately high internal consistency
(Weyer et al., 1997).
The exposure of interest is the baseline 2D surface data obtained from left/right hippocam-
pus. The hippocampus surface data were preprocessed from the raw MRI data, which were
collected across a variety of 1.5 Tesla MRI scanners with protocols individualized for each
scanner. Standard T1-weighted images were obtained by using volumetric 3-dimensional sagit-
tal MPRAGE or equivalent protocols with varying resolutions. The typical protocol includes:
inversion time (TI) = 1000 ms, flip angle = 8o, repetition time (TR) = 2400 ms, and field of view
(FOV) = 24 cm with a 256 × 256 × 170 acquisition matrix in the x−, y−, and z−dimensions
yielding a voxel size of 1.25 × 1.26 × 1.2 mm3. We adopted a surface fluid registration based
hippocampal subregional analysis package (Shi et al., 2013), which uses isothermal coordinates
and fluid registration to generate one-to-one hippocampal surface registration for surface statis-
tics computation. It introduced two cuts on a hippocampal surface to convert it into a genus
zero surface with two open boundaries. The locations of the two cuts were at the front and
back of the hippocampal surface. By using conformal parameterization, it essentially converts
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a 3D surface registration problem into a 2D image registration problem. The flow induced in
the parameter domain establishes high-order correspondences between 3D surfaces. Finally, the
radial distance was computed on the registered surface. This software package and associated
image processing methods have been adopted and described by various studies (Wang et al.,
2011; Shi et al., 2014; Monje et al., 2013). After preprocessing, we obtained left and right
hippocampal shape representations as two 100× 150 matrices.
In the ADNI data, there are millions of potential confounders that one may need to adjust
for, including the whole genome sequencing data from all of the 22 autosomes. For the genetic
data, we applied the following preprocessing technique to the 756 subjects in ADNI1 study. The
first line quality control steps include (i) call rate check per subject and per single nucleotide
polymorphism (SNP) marker, (ii) gender check, (iii) sibling pair identification, (iv) the Hardy-
Weinberg equilibrium test, (v) marker removal by the minor allele frequency, and (vi) popula-
tion stratification. The second line preprocessing steps include removal of SNPs with (i) more
than 5% missing values, (ii) minor allele frequency smaller than 10%, and (iii) Hardy-Weinberg
equilibrium p-value < 10−6. The 503,892 SNPs obtained from 22 autosomes were included
for further processing. MACH-Admix software (http://www.unc.edu/∼yunmli/MaCH-Admix/)
(Liu et al., 2013) is applied on all the subjects to perform genotype imputation, using 1000G
Phase I Integrated Release Version 3 haplotypes (http://www.1000genomes.org) (Consortium
et al., 2012) as reference panel. Quality control was also conducted after imputation, excluding
markers with (i) low imputation accuracy (based on imputation outputR2), (ii) Hardy-Weinberg
equilibrium p-value 10−6, and (iii) minor allele frequency < 5%. Finally, 6, 087, 205 bi-allelic
markers (including SNPs and indels) of 756 subjects were retained in the data analysis.
We deleted those subjects that have missingness of hippocampus shape representations or
ADAS-11 score observed at Month 24, ending up with 584 subjects for the analysis. Our aim
is to estimate the causal effect of the hippocampal surface exposure on the ADAS-11 score by
adjusting for clinical measures including age, gender and length of education, and a suitable
subset of the 6, 087, 205 bi-allelic markers using the method developed in the next section.
3 Methodology
3.1 Basic set-up
Suppose we observe independent and identically distributed samples {Li = (Xi,Zi, Yi), 1 ≤
i ≤ n} generated from L, where L = (X,Z, Y ) has support L = (X × Z × Y). Here
Z ∈ Z ⊆ Rp×q is a 2D-image continuous treatment/exposure, Y ∈ Y is a continuous outcome
of interest, and X ∈ X ⊆ Rs denotes a vector of ultra-high dimensional genetic (and clinical)
covariates, where we assume s >> n. We are interested in characterizing the causal effects of
the 2D exposure Z on the outcome Y .
Under the potential outcome framework, we define Y (z) to be the potential outcome that
would have been observed under treatment level z ∈ Z ⊆ Rp×q. For each unit, Yi = Yi(Zi)
corresponds to the potential outcome underZi, the level of treatment received. We are interested
in the mean potential outcome µ(z) = E[Y (z)], which we call effect surface.
We make the following assumptions for identifiability of effect surface, which are standard
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in the causal inference literature:
Assumption 1 (Stable Unit Treatment Value Assumption): Z = z implies Y = Y (z),
and there is only one version of treatment z.
Assumption 2 (Weak Ignorability): Y (z) ⊥ Z | X .
Assumption 3 (Positivity): pi(z | x) ≥ pimin > 0 for all x ∈ X and some constant pimin,
where pi(z | x) is the conditional treatment density given covariates X = x.
A directed acyclic graph showing the causal structure is given in Figure 2.
Under Assumptions 1–3, the effect surface can be identified with observed data as µ(z) =
EX [Q(z, X)], where Q(z, X) = E[Y | Z = z, X].
Figure 2: Directed acyclic graph showing potential high dimensional confounder X (yellow),
the 2D imaging exposureZ (green), and the outcome of interest Y (blue). The red arrow denotes
the causal effect of interest.
Denote Xi = (Xi1, . . . , Xis)T. Without loss of generality, we assume that Xil has been
standardized for every 1 ≤ l ≤ s, and Zi and Yi have been centered. To estimate E[Y | Z =
z, X], we assume the following linear regression models:
Yi =
s∑
l=1
Xilβl + 〈Zi,B〉+ i, (outcome generating model); (1)
Zi =
s∑
l=1
Xil ∗Cl +Ei, (treatment generating model). (2)
In (1), βl is the effect of the l-th potential confounder Xil on the behavioral outcome Yi,
B ∈ Rp×q is the coefficient matrix, representing effect of the 2D imaging treatment Zi on
the behavioral outcome Yi, and i is the random error. The inner product between two ma-
trices is defined as 〈Zi,B〉 = 〈vec(Zi), vec(B)〉, where vec(·) is a vectorization operator
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that stacks the columns of a matrix into a vector. Model (2), previously introduced in Kong
et al. (2020), builds the relationship between the 2D imaging treatment and the potential con-
founders. The Cl is a p × q coefficient matrix characterizing the effect of the lth covariate Xil
on the 2D imaging treatment Zi and Ei is a p × q matrix of random errors with mean 0. The
symbol “∗” denotes element-wise multiplication. Define M1 = {1 ≤ l ≤ s : βl 6= 0} and
M2 = {1 ≤ l ≤ s : Cl 6= 0}, where we assume |M1| < n and |M2| < n; here |M1|
and |M2| represent the number of elements in M1 and M2 respectively. Under models (1)
and (2), the effect surface can be expressed as µ(z) = 〈z,B〉. Therefore, the estimation of
E[Y | Z = z, X] boils down to estimation of the matrix coefficientB.
To obtain an unbiased estimate of the effect surface, the first step is to perform variable
selection in models (1) and (2). For all the covariatesXl, we can group them into four categories.
Let A = {1, . . . , s}, and denote C the indices of confounders, i.e. variables associated with
both the outcome and the exposure; P the indices of precision variables, i.e. predictors of
outcome, but not exposure; I the indices of instrumental variables, i.e. covariates that predict
the exposure, but not the outcome; S the indices of irrelevant variables, i.e. covariates that are
not related to both the outcome and the exposure. These sets can be written as C = {l ∈ A|βl 6=
0 and Cl 6= 0}, P = {l ∈ A|βl 6= 0 and Cl = 0}, I = {l ∈ A|βl = 0 and Cl 6= 0} and
S = {l ∈ A|βl = 0 and Cl = 0}.
The ideal adjustment set includes all confounders to avoid bias and all precision variables
to increase statistical efficiency, while excluding instrumental variables and irrelevant variables
(Brookhart et al., 2006; Shortreed and Ertefaie, 2017). In other words, we aim to retain all
covariates fromM1 = C ∪ P = {l ∈ A|βl 6= 0}, while excluding covariates from I ∪ S =
{l ∈ A|βl = 0}.
3.2 Naive screening methods
To find the nonzero βl’s, a straightforward idea is to consider a penalized estimator obtained
from the outcome generating model (1), where one imposes, say Lasso penalties, on βl’s. How-
ever, this is computationally infeasible in our ADNI data application as the number of baseline
covariates s is over 6 million.
Consequently, it is important to employ a screening procedure (e.g. Fan and Lv, 2008) to re-
duce the model size. To find covariates Xl’s that are associated with the outcome Y conditional
on the treatment Z, one might consider a conditional screening procedure for model (1) (Barut
et al., 2016). Specifically, one can fit the model Yi = Xilβl + 〈Zi,B〉 + i for each 1 ≤ l ≤ s,
obtain marginal estimates of β̂MZl ’s and then sort the |β̂MZl |’s for screening. This procedure
works well if the treatment variable Z is of low dimension as one only needs to fit low di-
mensional ordinary least squares (OLS) s times. However, in our ADNI data application, the
imaging treatment Z is of dimension pq = 15, 000, and one cannot obtain an OLS as n < pq.
Thus, to apply the conditional sure independence screening procedure to our application, one
may need to solve a penalized regression problem for each 1 ≤ l ≤ s, such as
argmin
B,βl
[
1
2n
n∑
i=1
(Yi − 〈Zi,B〉 −Xilβl)2 + Pλ(B)
]
, (3)
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where Pλ(B) is a penalty of B. One can then obtain the estimates β̂MZl,λ , and then rank the
|β̂MZl,λ |’s. The procedure will be repeated for s > 6, 000, 000 times in ADNI data, and is compu-
tationally prohibitive for two reasons. First, the penalized regression problem is much slower to
solve compared to the OLS. Second, selection of the tuning parameter λ based on grid search
substantially increases the computational burden.
Alternatively one may apply the marginal screening procedure of Fan and Lv (2008) to
model (1). Specifically, one may solve the following marginal OLS on each Xil by ignoring the
exposure Zi:
argmin
βl
[
1
2n
n∑
i=1
(Yi −Xilβl)2
]
. (4)
The marginal OLS estimate has a closed form β̂Ml = n
−1∑n
i=1XilYi, and one can rank |β̂Ml |’s
for screening. Specifically, the selected sub-model is defined as
M̂∗1 = {1 ≤ l ≤ s : |β̂Ml | ≥ γ1,n}, (5)
where γ1,n is a threshold. Computationally, it is much faster than conditional screening for
model (1) as we only need to fit one dimensional OLS for s > 6, 000, 000 times. However, the
procedure is likely to miss some important confounders. To see this, plugging model (2) into
(1) yields
Yi =
s∑
l=1
Xil(βl + 〈Cl,B〉) + 〈Ei,B〉+ i. (6)
Even in the ideal case when Xil’s are orthogonal for 1 ≤ l ≤ s, β̂Ml is not a good estimate of βl
because of the bias term 〈Cl,B〉. Thus, we may miss some nonzero βl’s in the screening step
if the effects of βl and 〈Cl,B〉 are of similar magnitudes but different signs. We illustrate this
point in Figures 6-7 in the simulations, in which cases the conventional marginal screening on
(1) fails to capture some of the true confounders.
3.3 Joint screening
To overcome the drawbacks of the estimation methods discussed in Section 3.2, we develop
a joint screening procedure, specifically for our ADNI data application. The procedure is
not only computationally efficient, but can also select all the confounders and precision vari-
ables with high probability. The key insight here is that although we are interested in select-
ing important variables in the outcome generating model, this can be done much more effi-
ciently by incorporating information from the treatment generating model. Specifically, let
ĈMl = n
−1∑n
i=1Xil ∗Zi ∈ Rp×q be the marginal OLS estimate in model (2) for l = 1, . . . , s.
Following Kong et al. (2020), the important covariates in model (2) can be selected by
M̂2 = {1 ≤ l ≤ s : ‖ĈMl ‖op ≥ γ2,n}, (7)
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where || · ||op is the operator norm of a matrix and γ2,n is a threshold. We then take the union of
covariates sets in (4) and (7) to define a new set
M̂ = M̂∗1 ∪ M̂2.
Intuitively, M̂∗1 includes all the important confounders and precision variables except for Xl’s,
for which both |β̂Ml | and ||Ĉl||op are large. These Xl’s, however, will be included in M̂2 and
hence also M̂. In Section 6, we show that with properly chosen γ1,n and γ2,n, P (M1 ⊂ M̂)→
1 as n → ∞. In practice, we recommend choosing γ1,n and γ2,n such that |M̂∗1| = |M̂2| = k,
where k is the smallest integer such that |M̂| ≥ bn/ log(n)c. The threshold bn/ log(n)c was
suggested by Fan and Lv (2008).
In general the set M̂ includes not only confounders and precision variables inM1 = C
⋃P ,
but also instrumental variables in I and a small subset of the irrelevant variables S . Neverthe-
less, the size |M̂| is greatly reduced compared to all the baseline covariates. For example, in our
data application, we reduce the s > 6, 000, 000 potential confounders to around 100 covariates
through our joint screening procedure. This makes it feasible to perform the second step in our
procedure, a refined penalized estimation ofB based on the covariates {Xil, l ∈ M̂}.
3.4 Estimation of causal effects
In this step, we aim to estimate the treatment effect by excluding the instrument variables I and
irrelevant variables in S from M̂ and keeping the remaining covariates. This can be done by
solving the following optimization problem
argmin
B,{βl,l∈M̂}
 1
2n
n∑
i=1
Yi − 〈Zi,B〉 −∑
l∈M̂
Xilβl
2 + λ1∑
l∈M̂
|βl|+ λ2||B||∗
 . (8)
Denote (B̂, β̂) the solution to the above optimization problem. The estimated effect surface is
given by µ̂(z) = 〈z, B̂〉. The Lasso penalty on βl is used to exclude instrumental and irrelevant
variables in M̂, whose corresponding coefficients βl’s are zero. The nuclear norm penalty ||·||∗,
defined as the sum of all the singular value of a matrix, is used to achieve a low-rank estimate of
B, where the low-rank assumption in estimating 2D structural coefficients is commonly used
in the literature (Chen et al., 2013; Zhou and Li, 2014; Kong et al., 2020).
To solve the minimization problem (8), we utilize the Nesterov optimal gradient method
(Nesterov, 1998), which has been widely used in solving optimization problems for non-smooth
and non-convex objective functions (Beck and Teboulle, 2009; Zhou and Li, 2014).
Denote l(β,B) = (2n)−1
∑n
i=1 (Yi − 〈β, Xi〉 − 〈Zi,B〉)2 and P (β,B) = P1(β)+P2(B),
where P1(β) = λ1
∑
l |βl| and P2(B) = λ2||B||∗. The objective function of (8) is denoted by
Q(β,B) = l(β,B) + P (β,B). In addition, let ∇l(β,B) = [(∂βl)T, {∂vec(B)l}T]T ∈ R|M̂|+pq
denotes the first-order gradient of l(β,B) with respect to [βT, {vec(B)}T]T ∈ R|M̂|+pq with
∂
∂β
l(β,B) = n−1
n∑
i=1
Xi (〈β, Xi〉+ 〈B,Zi〉 − Yi) ∈ R|M̂|, and
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∂∂vec(B)
l(β,B) = vec
{
n−1
n∑
i=1
Zi (〈β, Xi〉+ 〈B,Zi〉 − Yi)
}
∈ Rpq.
Let XM̂ = (XM̂1 , . . . , X
M̂
n )
T ∈ Rn×|M̂| where XM̂i is {Xij}Tj∈M̂ ∈ R|M̂| for i = 1, . . . , n.
Define Znew = (vec(Z1), . . . , vec(Zn))T ∈ Rn×pq and Xnew = (XM̂,Znew) ∈ Rn×(|M̂|+pq).
For a given vector a = (a1, . . . , ar)T ∈ Rr, (a)+ is defined as {(a1)+, . . . , (ar)+}T ∈ Rp, where
(a)+ = max(0, a). Similarly, sgn(a) is obtained by taking the sign of a componentwisely. For
a given pair of tuning parameters λ1 and λ2, (8) can be solved by Algorithm 1, whose detailed
derivation and explanation are included in the supplementary material.
Algorithm 1 Shrinkage thresholding algorithm to solve (8)
1. Initialize: β(0) = β(1),B(0) = B(1), α(0) = 0 and α(1) = 1,
δ = n/λmax(X
T
newXnew).
2. Repeat (a) to (f) until the objective function Q(β,B) converges:
(a) s(t) = β(t) + α
(t−1)−1
α(t)
(β(t) − β(t−1)),
S(t) = B(t) + α
(t−1)−1
α(t)
(B(t) −B(t−1));
(b) βtemp = s(t) − δ ∂l(s(t),B(t))∂β ;
vec(Btemp) = vec(S
(t))− δ ∂l(β(t),S(t))
∂vec(B)
;
(c) Singular value decomposition: Btemp = Udiag(B)VT;
(d) anew = sgn(βtemp) · (|βtemp| − λ1δ · 1)+,
bnew = (b− λ2δ · 1)+;
(e) β(t+1) = anew,
B(t+1) = Udiag(bnew)V
T;
(f) α(t+1) =
[
1 +
√
1 + (2α(t))2
]
/2.
A sufficient condition for the convergence of {β(t)}t≥1 and {B(t)}t≥1 is that the step size
δ should be smaller than or equal to 1/Lf , where Lf is the smallest Lipschitz constant of the
function l(β,B) (Beck and Teboulle, 2009). In our case, Lf is equal to λmax(XTnewXnew)/n,
where λmax(·) denotes the largest eigenvalue of a matrix.
For the tuning parameters, we use five-fold cross validation to select λ1 and λ2 based on a
two-dimensional grid search.
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4 ADNI data appliations
We use the data obtained from the ADNI study (adni.loni.usc.edu). The data usage acknowl-
edgement is included in Section ?? of the supplement material. As described in Section 2, our
data set includes 584 subjects from the ADNI1 study. The treatment of interest is the baseline
2D hippocampal surface radial distance measures, which can be represented as a 100×150 ma-
trix for each part of the hippocampus. The outcome of interest is the ADAS-11 score observed
at Month 24. The average ADAS-11 score is 14.4 with standard deviation 11.2. The potential
confounders to adjust for include 6, 087, 205 bi-allelic markers as well clinical covariates: age,
gender and education length. The average age is 75.5 years with standard deviation 6.7, and the
average education length is 15.7 years with standard deviation 2.9. Among all the 584 subjects,
58.2% is female. Studies have shown that age and gender are main risk factors for Alzheimer’s
disease (Vina and Lloret, 2010; Guerreiro and Bras, 2015) with older people and female more
likely to develop Alzheimer’s disease. Multiple studies have also shown that prevalence of de-
mentia is greater among those with low or no education (Zhang et al., 1990). On the other
hand, age, gender and length of education have been found to be strongly associated with the
hippocampal atrophy (Van de Pol et al., 2006; Jack et al., 2000; Noble et al., 2012). Therefore,
we include age, gender and education length as the confounders, and adjust for them in our
analysis. In addition, we also adjust for the population stratification, for which we use the top
five principal components of the whole genome data. As both left and right hippocampi have
2D radial distance measures and the two parts of hippocampi have been found to be asymmetric
(Pedraza et al., 2004), we apply our method to left and right hippocampi separately, i.e. treat
each part as a treatment and apply our procedure twice.
In particular, for each part of hippocampal outcome Yi, we regress both of our outcome Yi
and exposure Zi on the three clinical measures (age, gender and education length) as well as
the top five principal components of the whole genome data, to obtain the residual Y ∗i and Z
∗
i .
We then apply our joint screening procedure on those SNPs by treating Y ∗i and Z
∗
i as outcome
and exposure, respectively. In other words, the first step screening is only performed on the
6, 087, 205 SNPs. We choose the thresholds γ1,n and γ2,n such that |M̂| = bn/ log(n)c = 91.
In Table 1, we list the top 20 SNPs corresponding to left and right hippocampi respectively.
From Table 1, one can see that there are quite a few important SNPs found by analysis results
for both hippocampi. For example, the top SNP is the rs429358 from the 19th chromosome.
This SNP is a C/T single-nucleotide variant (snv) variation in the APOE gene, which is one
of the two SNPs that define the well-known APOE alleles, the major genetic risk factor for
Alzheimer’s disease (Kim et al., 2009). The SNP has also been found to be the most significant
SNP associated with Alzheimer’s disease (Kamboh et al., 2012). In addition, a great portion of
the SNPs in Table 1 have been found to be strongly associated with Alzheimer’s. These include
rs10414043 (Du et al., 2018), an A/G snv variation in the APOC1 gene; rs7256200 (Takei et al.,
2009), an A/G snv variation in the APOC1 gene; rs73052335 (Zhou et al., 2018), an A/C snv
variation in the APOC1 gene; rs769449 (Chung et al., 2014), an A/G snv variation in the APOE
gene; rs157594 (Hao et al., 2017), a G/T snv variation; rs56131196 (Gao et al., 2016; Herold
et al., 2016), an A/G snv variation in the APOC1 gene; rs111789331 (Gao et al., 2016; Lutz
et al., 2019), an A/T snv variation; and rs4420638 (Coon et al., 2007), an A/G snv variation in
the APOC1 gene.
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Left hippocampus Right hippocampus
Chromesome number SNP name Chromesome number SNP name
19 rs429358 19 rs429358
13 rs12864178 13 rs342709
22 rs134828 19 rs10414043
19 rs10414043 6 rs9386934
7 rs1016394 19 rs7256200
19 rs7256200 6 rs9374191
7 rs1181947 19 rs73052335
19 rs73052335 6 rs9372261
2 rs13030626 19 rs769449
19 rs769449 6 rs73526504
2 rs13030634 19 rs157594
19 rs157594 14 14:25618120:G GC
2 rs11694935 19 rs56131196
19 rs56131196 22 rs134828
2 rs11696076 19 rs4420638
19 rs4420638 16 rs194326
2 rs11692218 19 rs484195
19 rs484195 16 rs60922721
2 rs10495737 19 rs111789331
19 rs111789331 13 rs342705
Table 1: The top 20 SNPs selected through our joint screening procedure. The left two columns
correspond to results from the left hippocampus, and the right two columns correspond to results
from the right hipppocampus.
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Among those SNPs that have been found to be associated with Alzheimer’s, some of them
are also directly associated with hippocampi. For example, Zhou et al. (2020) revealed that
the SNPs rs10414043, rs73052335 and rs769449 are among the top SNPs that has significant
genetic effects on the volumes of both left and right hippocampi. Guo et al. (2019) identified
the SNP rs56131196 to be associated with hippocampal atrophy rate.
In addition, there are also a few SNPs found to be associated with hippocampi, though no
evidence in the literature shows that they are strongly related to Alzheimer’s. For example,
the SNP rs484195, a G/A/T/C snv variation in the APOC1 gene, was identified to strongly
associated to the volumes of both left hippocampus and right hippocampus (Yang et al., 2017).
The SNP rs10495737, a C/T snv variation on chromosome 2, was among the top SNPs that are
associated with the left hippocampal surface (Huang et al., 2017).
We then perform our second-step estimation procedure for each part of the hippocampi. In
particular, we let XM̂ be those selected SNPs, the population stratification (top five principal
components of the whole genome data) and the clinical measures age, gender and education
and Z be the left/right hippocampal surface image matrix. We use five fold cross validation
to select λ1 and λ2. The estimates B̂’s corresponding to each hippocampus are mapped onto
a representative hippocampal surface and plotted in Figure 3(a). We have also plotted the hip-
pocampal subfield (Apostolova et al., 2006) in Figure 3(b). From the result, one can see that
the atrophies of CA1 as well as the subiculum subregions increase the ADAS-11 score, which
translates to more severe behavioral deficits. Existing literature (Scho¨nheit et al., 2004; Apos-
tolova et al., 2010) has found that as Alzheimer’s disease progresses, it first affects CA1 and
subiculum subregions and later CA2 and CA3 subregions. This can partially explain why the
atrophy of CA1 and subiculum may cause more severe behavioral deficits compared to CA2
and CA3 subregions.
For comparison, we conduct mediation analysis (Bi et al., 2017) using the same dataset.
The mediation analysis considers the same variables, but takes the genetic covariates as the
treatment, and studies causal effects of genetic factors on behavioral deficits, disentangling the
total effect of genetic factors on the behavioral outcome into a direct effect and an indirect
effect operating through the hippocampal imaging mediator. A directed acyclic graph showing
the mediation structure is given in Figure 4.
We take each element of imaging treatment Z as an intermediate imaging measure, and in
total we have 30, 000 scans for left and right hippocampi (15, 000 each). Following Bi et al.
(2017), linear structural equation models are assumed for the relationships among each of the
genetic variants, each of the 30, 000 scans and the behavior score, while conditioning on partic-
ipants age, gender, education length and the top five principal components of the whole genome
data corresponding to population stratification. The p-value for each SNP effect was deter-
mined by the Wald test. A threshold of p-value is considered for significance after Bonferroni
correction, controlling for the 6, 087, 205 SNPs.
Similar to Bi et al. (2017), we identified the pairs of SNP and imaging measure, for which
the direct effect of SNP on behavioral outcome, the effect of SNP on imaging measure and the
effect of imaging measure on the behavioral outcome are all significant. We list those SNPs
with at least one paired imaging measure (i.e. hippocampal imaging pixel) in Table 2.
One can see most of the SNPs in Table 2 are also selected by our procedure, including SNPs
rs429358, rs4420638, rs56131196, rs73052335, rs10414043 and rs7256200. As the mediation
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Figure 3: Real Data Results: Panel (a) plots the effect estimate B̂ corresponding to the left
hippocampus (left part) and the right hippocampus (right part). Panel (b) plots the hippocampal
subfield.
Figure 4: Directed acyclic graph showing potential high dimensional (genetic) exposure X
(green), the 2D imaging mediator Z (purple), and the outcome of interest Y (blue). The red
arrows denote the direct and indirect causal effects of interest.
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Chromesome number SNP name
19 rs429358
19 rs4420638
19 rs56131196
19 rs6857
19 rs12721051
19 rs73052335
19 rs10414043
19 rs7256200
19 rs59007384
Table 2: The SNPs selected through mediation analyses. We include all SNPs that have at least
one paired imaging measure.
analysis can be used to find a subset of confounders, while our method aims to select the set of
true confounders and precision variables, these SNPs selected by both procedures are likely to
be confounders.
5 Simulation studies
In this section, we perform simulation studies to evaluate the finite sample performance of
the proposed method. The dimension of potential confounders is set as s = 5000, and the
treatment is a 64× 64 matrix. The Xi ∈ Rs is independently generated from N(0,Σx), where
Σx = (σx,ll′) has an autoregressive structure such that σx,ll′ = ρ
|l−l′|
1 holds for 1 ≤ l, l′ ≤ s
with ρ1 = 0.5. Define B∗ as a 64 × 64 image shown in Figure 5(a), and C∗ a 64 × 64 image
shown in Figure 5(b), where the black regions of interest (ROIs) are assigned value one and
white ROIs are assigned value zero. Further let C as C∗/‖C∗‖F , and we set C˙l = vl ∗ C,
where v1 = −1/3, v2 = −1, v3 = −3, v207 = −3, v208 = −1, v209 = −1/3, and vl = 0 for
4 ≤ l ≤ 206 and 210 ≤ l ≤ s. The true coefficient matrix B˙ is set as B∗/‖B∗‖F . We set
β˙1 = 3, β˙2 = 1, β˙3 = 1/3, β˙104 = 3, β˙105 = 1, β˙106 = 1/3, and β˙l = 0 for 4 ≤ l ≤ 103 and
107 ≤ l ≤ s. In this setting, we have C = {1, 2, 3}, P = {104, 105, 106}, I = {207, 208, 209}
and S = {1 . . . , 5000}\{1, 2, 3, 104, 105, 106, 207, 208, 209}.
The random error vec(Ei) is independently generated from N(0,Σe), where we set the
standard deviations of all elements in Ei to be σe = 0.2 and the correlation between Ei,jk
and Ei,j′k′ to be ρ
|j−j′|+|k−k′|
2 for 1 ≤ j, k, j′, k′ ≤ 64 with ρ2 = 0.5. The random error i is
generated independently from N(0, σ2), where we consider σ2 = 1 or 0.25. The Yi’s and Zi’s
are generated from models (1) and (2). We consider three different sample sizes n = 200, 500
and 1000.
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(a) (b)
Figure 5: Panels (a) and (b) plot B∗ and C∗ respectively. The value at each pixel is either 0
(white) or 1 (black).
5.1 Simulation for screening
We perform our screening procedure (denoted by “union”) and report the coverage proportion
of M1, which is defined as |M̂∩M1||M1| , where the size of the selected set |M̂| changes from 1
to 100. In addition, we report the coverage proportion for each of the confounding and preci-
sion variables, i.e. each of the j’s in the set M1 = {1, 2, 3, 104, 105, 106}. All the coverage
proportions are averaged over 100 Monte Carlo runs.
To control the changing size of the |M̂|, we first set |M̂∗1| = |M̂2| = 1 by specifying
appropriate γ̂1,n and γ̂2,n. Then we sequentially add two variables, one to M̂∗1 by increasing
γ̂1,n and one to M̂2 by increasing γ̂2,n, until |M̂| reaches 100. Note that we always keep
|M̂∗1| = |M̂2| in the procedure. We may not obtain all the sizes between 1 to 100 because |M̂|
may increase by at most 2. Therefore, for those sizes that cannot be reached, we use a linear
interpolation to estimate the coverage proportion ofM by using the closest two end points.
We compare the proposed joint screening procedure to two competing procedures. The
first is an outcome screening procedure that selects set M̂∗1. For fair comparison, we let |M̂∗1|
range from 1 to 100. The second is an intersection screening procedure, that selects set M̂∩ =
M̂∗1 ∩ M̂2. We let |M̂∩| range from 1 to 100, while keeping |M̂∗1| = |M̂2|. Similarly, for
those specific sizes that |M̂∗| cannot reach, we use linear interpolation to estimate the coverage
proportions. We plot the results for cases in Figures 6 and 7: (n, s, σ2) = (200, 5000, 1) and
(1000, 5000, 1). The remaining results, in which (n, s, σ2) = (200, 5000, 0.25), (500, 5000, 1),
(500, 5000, 0.25) and (1000, 5000, 0.25), can be found in Figures ??-?? of the supplementary
material.
From the plots, one can see that both the “intersection” and “outcome” methods miss the
confounder X3 with a very high probability even as the size of the selected set approaches
100. In contrast, our method can select X3 with high probability when |M̂| is relatively small.
For confounders X1 and X2, all three methods perform similarly. For the precision variables,
the “outcome” method and our “union” method performs similarly in covering these variables,
while the “intersection” performs badly. Combining the results, one can see that our method
performs the best as our method selects all the confounders and precision variables with high
probabilities. In addition, we find that the coverage proportion of our method increases when
the sample size increases, which validates the sure independence screening property developed
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(a) Confounder: strong
outcome, weak exposure
(b) Confounder: medium
outcome, medium exposure
(c) Confounder: weak
outcome, strong exposure
(d) Precision: strong
outcome, zero exposure
(e) Precision: medium
outcome, zero exposure
(f) Precision: weak
outcome, zero exposure
(g)
Figure 6: Simulation results for the case (n, s, σ2) = (200, 5000, 1): Panels (a) – (f) plot the av-
erage coverage proportion forXl, where l = 1, 2, 3, 104, 105 and 106. Panels (a)-(c) correspond
to strong outcome and weak exposure predictor, moderate outcome and moderate exposure pre-
dictor and weak outcome and strong exposure predictor; Panels (d)-(f) correspond to strong,
moderate and weak predictors of outcome only. Panel (g) plots the average coverage proportion
for the index setM1 = {1, 2, 3, 104, 105, 106}. The x-axis represents the size of M̂, while y-
axis denotes the average proportion. The green solid, the red dashed and the black dash dotted
lines denote our union screening method, the outcome screening method, and the intersection
screening method, respectively. 19
(a) Confounder: strong
outcome, weak exposure
(b) Confounder: medium
outcome, medium exposure
(c) Confounder: weak
outcome, strong exposure
(d) Precision: strong
outcome, zero exposure
(e) Precision: medium
outcome, zero exposure
(f) Precision: weak
outcome, zero exposure
(g)
Figure 7: Simulation results for the case (n, s, σ2) = (1000, 5000, 1): Panels (a) – (f) plot
the average coverage proportion for Xl, where l = 1, 2, 3, 104, 105 and 106. Panels (a)-(c)
correspond to strong outcome and weak exposure predictor, moderate outcome and moderate
exposure predictor and weak outcome and strong exposure predictor; Panels (d)-(f) correspond
to strong, moderate and weak predictors of outcome only. Panel (g) plots the average coverage
proportion for the index set M1 = {1, 2, 3, 104, 105, 106}. The x-axis represents the size of
M̂, while y-axis denotes the average proportion. The green solid, the red dashed and the black
dash dotted lines denote our union screening method, the outcome screening method, and the
intersection screening method, respectively. 20
in Section 6.
5.2 Simulation for estimation
In this part, we evaluate the performance of our estimation procedure after the first-step screen-
ing. For the size of M̂ in the screening step, we set |M̂| = bn/ log(n)c, so that |M̂| = 37, 80
and 144 for sample sizes n = 200, 500 and 1000, respectively. We report the mean squared
errors (MSEs) for β andB defined as ||β˙ − β̂||22 and ‖B˙ − B̂‖2F , respectively.
Table 3 summarizes the average MSEs for β and B among 100 Monte Carlo runs. We
can see that the MSE decreases with the sample size, which validates the consistency results
developed in Section 6.
Table 3: Simulation results for σ2 = 1 and σ2 = 0.25: the average MSEs for β andB, and their
associated standard errors in the parentheses are reported. The results are based on 100 Monte
Carlo repetitions.
σ2 = 1.0 MSE β MSEB σ2 = 0.25 MSE β MSEB
n=200 0.415(0.015) 0.826(0.028) n=200 0.254(0.010) 0.640(0.013)
n=500 0.275(0.006) 0.682(0.015) n=500 0.158(0.007) 0.405(0.006)
n=1000 0.204(0.006) 0.526(0.014) n=1000 0.077(0.005) 0.287(0.003)
6 Theoretical properties
6.1 Sure screening property
In this subsection, we study theoretical properties for our screening procedure. We letM1 =
{1 ≤ l ≤ sn : β˙∗l 6= 0} = C˙ ∪ P˙ , where C˙ = {1 ≤ l ≤ sn : C˙l 6= 0 and β˙∗l 6= 0} and
P˙ = {1 ≤ l ≤ sn : C˙l = 0 and β˙∗l 6= 0}. Here β˙∗l and C˙l are the true values for βl and Cl,
respectively, and B˙ is the true value ofB.
We have the following theorems, where the assumptions needed are included in Section ??
of the supplementary material.
Theorem 1. Under Assumptions (A0) - (A3) and (A5), let γ1,n = αD1n−κ and γ2,n = αD1(pq)1/2
n−κ with 0 < α < 1, then we have P (M1 ⊂ M̂)→ 1 as n→∞.
Since the screening procedure automatically includes all the significant covariates for small
value of γ1,n and γ2,n, it is necessary to consider the size of M̂, which we quantify in Theorem
2.
Theorem 2. Under Assumptions (A0) - (A5), when γ1,n = αD1n−κ and γ2,n = αD1(pq)1/2n−κ
with 0 < α < 1, we have P (|M̂| = O(n2κ+τ ))→ 1 as n→∞.
Theorem 1 shows that if γ1,n and γ2,n are chosen properly, our screening procedure will
include all significant variables with a high probability. Theorem 2 guarantees that the size of
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selected model from the screening procedure is only of a polynomial order of n even though
the original model size is of an exponential order of n. Therefore, the false selection rate of
our screening procedure vanishes as n→∞, while the size of M̂ grows in a polynomial order
of n, where the order depends on two constants κ and τ defined in the supplementary material.
The proofs of these two theorems are collected in the supplementary material as well.
6.2 Theory for two-step estimator
In this section, we develop a unified theory for our two-step estimator. In particular, we derive
a non-asymptotic bound for the final estimates. We first introduce some notation.
Denote parameter θ = {βT, vecT(B)}T ∈ Rs+pq, where β ∈ Rs and B ∈ Rp×q. Us-
ing this notation, problem (8) can be recasted as minimizing l(θ) + P (θ), where l(θ) =
(2n)−1
∑n
i=1 (Yi − 〈Zi,B〉−
∑
l∈M̂ Xilβl
)2, and P (θ) = λ1∑l∈M̂ |βl| + λ2||B||∗. In ad-
dition, we let θ˙ = {β˙T, vec(B˙)T}T be the true value for θ, where β˙ and B˙ is the true values
for β andB, respectively. Let θ̂λ = {β̂T, vec(B̂}T)T be the proposed estimator for θ, where β̂
and B̂ are the estimators obtained from (8) for tuning parameters λ = (λ1, λ2).
We hereby give nonasymptotic error bound for the proposed two-step estimator θ̂λ:
Theorem 3. (Nonasymptotic error bounds for two-step estimator) Under Assumptions (A0) -
(A9), and 2κ + τ < 1 and κ < 1/4, there exists some positive constants c1, c2, c3, c4, C0,
C1, g0 and g1, such that for λ1 ≥ 2σ0[2n−1{log(log n) + C0(2κ + τ) log n}]1/2 and λ2 ≥
2bs2σ0[2n
−1{3 log s2 + log(log n)}]1/2 + 4n−1/2 σ(p1/2 + q1/2), with probability at least 1 −
c1/ log n− c2/(s2 log n)− c3 exp{−c4(p+ q)} − exp(−n)− g0 exp(−g1n1−2κ), one has∥∥∥θ̂λ − θ˙∥∥∥2
2
≤ C0max
{
C1λ
2
1n
2κ+τ , λ22r
}
ι−2.
The bound in Theorem 3 implies that the convergence rate of the proposed estimator θ̂λ is
O(max{ n2κ+τ−1, n1−2τ}). Here ι is a positive constant as defined in Assumption (A6) in the
supplementary material, and r is the rank of B˙. The convergence rate is controlled by κ and
τ , where κ controls the exponential rates of model complexity that can diverge and τ controls
the rate of largest eigenvalue of population covariance matrix that can grow. The proof of the
theorem is deferred to the supplementary material.
7 Discussion
This paper answers the question whether (and how) hippocampal atrophy affects behavorial
deficits in Alzheimer’s studies. With the hippocampal morphemetry surface measure as an
exposure, the proposed causal inference procedure is successfully applied to the ADNI data
analysis and identifies important genetic biomarkers that need to be adjusted for in causal infer-
ence and located subregions of the hippocampus that may be causally associated with behav-
ioral deficits. To the best of our knowledge, this is the first causal inference approach for 2D
high-dimensional continuous treatment with ultra-high dimensional potential confounders. The
22
unique features of the data motivate us to develop a computationally efficient two-step screen-
ing and estimation procedure, which can select biomarkers among more than 6 million potential
confounders and estimate the causal effect simultaneously.
There are a number of important directions for future work. First, in this article, we as-
sume that the potential genetic confounders only have main effects on both the treatment and
the outcome. Further investigation is warranted to extend the proposed approach to the case
with interaction effects, which is of great scientific interest in genome-wide association studies
(Cordell, 2009). Second, it is an interesting topic to study the statistical inference procedure for
our causal estimates and characterize the uncertainty of the causal estimand. One may consider
either bootstrap or debiased approaches (Chatterjee and Lahiri, 2011; Van de Geer et al., 2014).
Note that existing approaches focus on the `1 penalization, whereas our estimation procedure
is a combination of `1 sparse and nuclear norm low-rank penalization. Extending existing ap-
proaches to the low-rank case is highly non-trivial. Third, in the ADNI dataset, there are lon-
gitudinal ADAS-11 scores observed at different months and also other longitudinal behavioral
scores obtained from Mini-Mental State Examination and Rey Auditory Verbal Learning Test,
which can provide a more comprehensive characterization of the behavioral deficits. Integrat-
ing these different scores as a multivariate longitudinal outcome requires substantial effort for
further invesitgation. Fourth, this study simply removes observations that have missingness.
Accommodation of missing treatment, confounders and outcome under the proposed model
framework is of great practical value, and we leave it for future research. Finally, it would
be interesting to extend the current approach to MRI or fMRI imaging exposure, where one
can combine the joint screening procedure with a second-step estimation procedure for tensor-
valued images (Feng et al., 2020).
Supplementary Material
Supplementary Material available online contains detailed derivation and explantion of the
Algorithm 1, ADNI data usage acknowledgement, additional simulation results, assumptions
needed for our main theorems, and proofs of auxiliary lemmas and main theorems.
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